Topiramate
Tier B — Position earlyTopiramate
Targets：Kainic acid receptor, CA4, GABAAR, CA2, AMPAR, CAs, GABAT, Sodium channels
Brand：Topina, Topamax, Eprontia, Conviban, Qudexy
Indications (approved)：Epilepsy, Lennox-Gastaut syndrome, Seizure, Tonic-clonic seizure, Partial-onset seizure, Migraine
Regional status
Synthetic routes & intermediates5 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| TOPIR-001 | 20880-92-6 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methanol |
| TOPIR-002 | 7778-42-9 | sulfamoyl chloride |
| Code | CAS No. | Intermediate |
|---|---|---|
| TOPIR-001 | 20880-92-6 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methanol |
| TOPIR-003 | 7803-58-9 | sulfuric diamide |
| Code | CAS No. | Intermediate |
|---|---|---|
| TOPIR-001 | 20880-92-6 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methanol |
| TOPIR-004 | 150609-95-3 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl sulfochloridate |
| Code | CAS No. | Intermediate |
|---|---|---|
| TOPIR-001 | 20880-92-6 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methanol |
| TOPIR-005 | 1189-71-5 | sulfurisocyanatidic chloride |
| TOPIR-006 | 100-61-8 | N-methylaniline |
| TOPIR-007 | 40028-34-0 | (methyl(phenyl)carbamoyl)sulfamoyl chloride |
| TOPIR-008 | 876403-99-5 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl methyl(phenyl)carbamoylsulfamate |
| Code | CAS No. | Intermediate |
|---|---|---|
| TOPIR-001 | 20880-92-6 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methanol |
| TOPIR-005 | 1189-71-5 | sulfurisocyanatidic chloride |
| TOPIR-009 | 89979-13-5 | benzyl chlorosulfonylcarbamate |
| TOPIR-010 | 627537-93-3 | ((3aS,5aR,8aR,8bS)-2,2,7,7-tetramethyltetrahydro-3aH-bis([1,3]dioxolo)[4,5-b:4',5'-d]pyran-3a-yl)methyl (benzyloxy)carbonylsulfamate |
Frequently asked questions
What are the approved indications of Topiramate?
Approved indications include: Epilepsy, Lennox-Gastaut syndrome, Seizure, Tonic-clonic seizure, Partial-onset seizure, Migraine.
When does the Topiramate patent expire?
No public expiry year is available for Topiramate yet; this page updates once verified.
How many synthesis routes are recorded for Topiramate?
5 synthesis routes are recorded; the shortest is 1 steps with 45.1 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Topiramate intermediates?
All intermediates in Topiramate routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Topiramate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-04